Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Onvansertib · PCM-075, NMS-1286937

Small molecule · Inhibitor of polo-like kinase 1 (PLK1) · developed by Cardiff Oncology

Phase 2 Most advanced trial
CRDF Developer
2 Registered trials

What is Onvansertib?

Onvansertib is an orally bioavailable, ATP-competitive inhibitor of polo-like kinase 1 (PLK1), a serine/threonine kinase that regulates mitosis. By inhibiting PLK1 it disrupts mitosis, causing G2/M arrest and apoptosis in PLK1-overexpressing tumor cells. It is being studied in small-cell lung cancer and metastatic colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PCM-075, NMS-1286937
Drug type
Small molecule
Targets
polo-like kinase 1 (PLK1)
Mechanism
Inhibitor of polo-like kinase 1 (PLK1)
Pathways
mitosis regulation, G2/M cell-cycle arrest, apoptosis
Therapy area
Oncology
Developer
Cardiff Oncology (CRDF)
Also in trials of
PFE
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
67RM91WDHQ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06106308 Phase 2 Metastatic Colorectal Cancer Active not recruiting PFE
NCT05450965 Phase 2 Small-cell Lung Cancer Recruiting CRDF

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CRCKRAS/NRAS MutationMetastatic Colorectal CancerSmall Cell Lung CarcinomaSmall-cell Lung Cancer

Other drugs acting on PLK1

More from Cardiff Oncology

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the CRDF page.

Follow CRDF, the company behind Onvansertib

See CRDF's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRDF catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.